Open AccessMultivesicular liposome formulations for the sustained delivery of interferon α‐2b 1
Author(s) -
QIU Jian,
WEI Xiaohui,
GENG Fang,
LIU Rui,
ZHANG Jingwu,
XU Yuhong
Publication year - 2005
Publication title -
acta pharmacologica sinica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.514
H-Index - 90
eISSN - 1745-7254
pISSN - 1671-4083
DOI - 10.1111/j.1745-7254.2005.00188.x
Subject(s) - in vivo , liposome , alpha (finance) , alpha interferon , pharmacology , interferon , subcutaneous injection , medicine , chemistry , immunology , biology , biochemistry , surgery , construct validity , microbiology and biotechnology , patient satisfaction
Aim: To develop and optimize a sustained release multivesicular liposome (MVL) formulation of interferon (IFN) α‐2b. Methods: IFN α‐2b MVL were prepared using a typical double‐emulsion procedure. The sustained release effects of IFN α‐2b MVL were investigated by monitoring the blood IFN α‐2b concentration using an enzyme‐linked immunosorbent assay test after subcutaneous administration to healthy mice. Results: IFN α‐2b was successfully encapsulated in MVL with high efficiency, and the integrity of encapsulated protein was maintained. After subcutaneous injection, the MVL slowly released IFN α‐2b into systemic circulation in a sustained manner. The estimated serum half‐life of IFN α‐2b was approximately 30 h. In addition, varying the size of the MVL preparations could further modify the in vivo release profile. Conclusion: IFN α‐2b MVL may be a useful sustained release formulation in the clinical treatment of viral diseases.